Cardiac technology company HeartBeam Inc (NASDAQ:BEAT) said on Tuesday that it has acquired substantially all assets of LIVMOR, a digital health solutions company that provides a patient-engaging remote monitoring system of critical physiological biomarkers.
This acquisition extends HeartBeam's operations in remote monitoring and detection with full ownership of the Halo+ Atrial Fibrillation (AF) Detection System, a prescription wearable for continuous cardiac rhythm monitoring which is cleared by the US Food and Drug Administration (FDA).
Financial terms of the deal were not disclosed.
In February 2022, HeartBeam partnered with LIVMOR to build a HeartBeam-branded version of LIVMOR's Halo cloud-based software platform to connect physicians and patients. With the Halo cloud-based platform, HeartBeam was able to meet its schedule for FDA submission of the HeartBeam AIMI software for acute care settings that provides a 3D vector electrogram (VECG) comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack.
Under the terms of the acquisition agreement, HeartBeam purchased three issued US patents, LIVMOR's technology, including the Halo AF Detection System, its business contracts and relationships, as well as all Samsung watch and tablet inventory. HeartBeam also hired LIVMOR's key technical employees.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia